PURPOSE: To evaluate the morphological and functional changes following intravitreal Ozurdex (dexamethasone implant) injections in patients with macular oedema (MO) secondary to retinal vascular diseases. DESIGN: This is a single centre, exploratory phase III, prospective, open-label clinical study. METHODS: Thirty patients with MO secondary to retinal vascular disorders underwent assessments for best corrected visual acuity, contrast sensitivity, microperimetry, chromatic sensitivity, macular thickness, and morphology using spectral domain optical coherence tomography (SD-OCT) and fluorescein angiography at baseline. They were treated with intravitreal Ozurdex at baseline and monitored monthly with visual acuity and SD-OCT assessments up to 36 weeks. Re-treatment was permitted from 16 to 24 weeks according to pre-defined criteria. All visual function tests were repeated at 24 weeks. RESULTS: The mean change in central sub-field thickness (CST) from baseline was significant at all visits up to 32 weeks. The lowest mean CST was recorded at 8 weeks and the highest mean ETDRS score was achieved at 12 weeks. All visual functions except contrast sensitivity improved significantly by 24 weeks. The study showed that the ideal re-treatment time point based on functional and structural outcomes and known side-effects of Ozurdex treatment is at 20 weeks. CONCLUSION: Ozurdex therapy has a rapid and dramatic effect on the macula for about 8 weeks followed by a sustained modest effect up to week 32. The optimal re-treatment time point is at 20 weeks.
PURPOSE: To evaluate the morphological and functional changes following intravitreal Ozurdex (dexamethasone implant) injections in patients with macular oedema (MO) secondary to retinal vascular diseases. DESIGN: This is a single centre, exploratory phase III, prospective, open-label clinical study. METHODS: Thirty patients with MO secondary to retinal vascular disorders underwent assessments for best corrected visual acuity, contrast sensitivity, microperimetry, chromatic sensitivity, macular thickness, and morphology using spectral domain optical coherence tomography (SD-OCT) and fluorescein angiography at baseline. They were treated with intravitreal Ozurdex at baseline and monitored monthly with visual acuity and SD-OCT assessments up to 36 weeks. Re-treatment was permitted from 16 to 24 weeks according to pre-defined criteria. All visual function tests were repeated at 24 weeks. RESULTS: The mean change in central sub-field thickness (CST) from baseline was significant at all visits up to 32 weeks. The lowest mean CST was recorded at 8 weeks and the highest mean ETDRS score was achieved at 12 weeks. All visual functions except contrast sensitivity improved significantly by 24 weeks. The study showed that the ideal re-treatment time point based on functional and structural outcomes and known side-effects of Ozurdex treatment is at 20 weeks. CONCLUSION:Ozurdex therapy has a rapid and dramatic effect on the macula for about 8 weeks followed by a sustained modest effect up to week 32. The optimal re-treatment time point is at 20 weeks.
Authors: Adam Martidis; Jay S Duker; Paul B Greenberg; Adam H Rogers; Carmen A Puliafito; Elias Reichel; Caroline Baumal Journal: Ophthalmology Date: 2002-05 Impact factor: 12.079
Authors: Nicolette Binz; Caroline E Graham; Ken Simpson; Yvonne K Y Lai; Wei-Yong Shen; Chooi-May Lai; Terence P Speed; P Elizabeth Rakoczy Journal: FASEB J Date: 2005-12-14 Impact factor: 5.191
Authors: David J Browning; Adam R Glassman; Lloyd Paul Aiello; Roy W Beck; David M Brown; Donald S Fong; Neil M Bressler; Ronald P Danis; James L Kinyoun; Quan Dong Nguyen; Abdhish R Bhavsar; Justin Gottlieb; Dante J Pieramici; Michael E Rauser; Rajendra S Apte; Jennifer I Lim; Päivi H Miskala Journal: Ophthalmology Date: 2006-11-21 Impact factor: 12.079
Authors: Ingrid U Scott; Michael S Ip; Paul C VanVeldhuisen; Neal L Oden; Barbara A Blodi; Marian Fisher; Clement K Chan; Victor H Gonzalez; Lawrence J Singerman; Michael Tolentino Journal: Arch Ophthalmol Date: 2009-09
Authors: J Ramu; Y Yang; G Menon; C Bailey; N Narendran; C Bunce; A Quartilho; A T Prevost; P Hykin; S Sivaprasad Journal: Eye (Lond) Date: 2015-10-23 Impact factor: 3.775
Authors: Albert J Augustin; Baruch D Kuppermann; Paolo Lanzetta; Anat Loewenstein; Xiao-Yan Li; Harry Cui; Yehia Hashad; Scott M Whitcup Journal: BMC Ophthalmol Date: 2015-10-30 Impact factor: 2.209
Authors: Nicole Eter; Andreas Mohr; Joachim Wachtlin; Nicolas Feltgen; Andrew Shirlaw; Richard Leaback Journal: Graefes Arch Clin Exp Ophthalmol Date: 2016-07-26 Impact factor: 3.117